SMS Pharmaceuticals Ltd receives EIR from USFDA for Central Laboratory Analytical Services

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE:532815) is pleased to announce the successful closure of the recent inspection by the USFDA at its Central Laboratory Analytical Services, Gagillapur, Hyderabad, with the receipt of the Establishment Inspection Report (EIR).

The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations, as previously intimated to the stock exchanges. The company has received the Establishment Inspection Report (EIR) with "No Action Indicated" (NAI) status, marking the closure of the audit.

Commenting on this achievement, Mr. P. Vamsi Krishna, Executive Director, stated: "The successful completion of the recent USFDA inspection underscores our unwavering commitment to the highest standards of quality, regulatory compliance, and operational excellence across our manufacturing and analytical facilities. This positive outcome reinforces the confidence of our global partners and stakeholders, while further enabling our strategic growth and sustained presence in key regulated markets."

Shares of SMS Pharmaceuticals Limited was last trading in BSE at Rs. 231.25 as compared to the previous close of Rs. 234.10. The total number of shares traded during the day was 1089 in over 49 trades.

The stock hit an intraday high of Rs. 233.20 and intraday low of 230.00. The net turnover during the day was Rs. 252107.00.

Source : Equity Bulls

Keywords

SMSPharmaceuticals INE812G01025 USFDA EIR CentralLaboratoryAnalyticalServices